A groundbreaking new test has been developed to diagnose acute promyelocytic leukemia (APL), a rare and aggressive form of blood cancer, using CRISPR technology. This innovative test, called RAPID-CRISPR, can deliver results in under three hours and is cheaper than current testing methods, making it a game changer for patients, especially in developing countries.
Acute promyelocytic leukemia is characterized by a genetic mutation that causes a dangerous fusion of two genes, PML and RARA. This mutation leads to a decrease in white blood cells and platelets, which can severely weaken the body’s ability to fight infections and stop bleeding. Without prompt diagnosis and treatment, APL can lead to severe internal bleeding and even death within days.
The typical diagnosis of APL can take a long time and requires expensive equipment and trained staff, which are not always available in rural or less developed areas. However, the RAPID-CRISPR test, developed by researchers at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) in Mumbai, addresses this issue.
The RAPID-CRISPR test works by adding a patient’s blood sample to a solution that targets the PML-RARA gene mutation. When the mutation is present, the test uses CRISPR technology to cut the mutated gene, producing a detectable signal on a simple strip, similar to a home pregnancy test. This method allows for easy reading of results without the need for complex laboratory setups.
In trials, the RAPID-CRISPR test was successful in correctly identifying APL in all tested samples, demonstrating nearly 100% sensitivity and specificity. It was even able to detect the mutation when only a single copy was present, proving to be ten times more sensitive than existing gold-standard tests.
The introduction of the RAPID-CRISPR test is expected to make a significant impact on how quickly and effectively APL can be diagnosed, particularly in regions with limited medical resources. By simplifying the testing process and lowering costs, this new method can help ensure that patients receive timely treatment.
Researchers are optimistic that with further development, RAPID-CRISPR could become standard practice in hospitals worldwide, and there are even plans to eventually offer at-home testing options. This advancement in medical technology represents a hopeful shift in the fight against acute promyelocytic leukemia and a step toward more accessible cancer diagnosis and treatment for all.
